A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies
Latest Information Update: 17 Aug 2022
At a glance
- Drugs XYF 19 CAR-T cell therapies Yufan Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
Most Recent Events
- 17 Jun 2022 Results from dose escalation part presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 Aug 2019 New trial record